Cabotegravir (CAB-LA), the first long-acting injectable pre-exposure prophylaxis (PrEP), has been approved for use in the USA and is not currently on the market in China. However, willingness to use CAB-LA and associated factors among men who have sex with men (MSM) have not yet been evaluated in China. A cross-sectional study was conducted in Guangxi, China, in 2022 recruiting 1,006 MSM. Their mean age was 30.2 years, 74.2% had college or above education, and 48.6% had a monthly income between 3,000 and 5,999 Chinese yuan (CNY). Most (73.4%) had previously heard of PrEP while few (8.3%) had ever used this type of preventative medication. Willingness to use CAB-LA was 79.8% and was positively associated with eight variables: younger age, being married to a woman, having a low monthly income, having six or more male partners in the past six months, having only regular male partners in the past month, having a high perceived risk of HIV infection, and history of using PrEP. Ten other variables were not significantly associated with willingness to use CAB-LA. Among 894 participants who were willing to use or did not definitely reject using CAB-LA, the main concerns about CAB-LA were its side effects (90.2%), efficacy (63.6%), and high cost (58.2%). Only 14.7% were willing to pay more than 1,200 CNY (~US$180) every two months to use CAB-LA. The preferred injection places were centers for disease control facilities, hospitals, and social organizations. Many (89.0%) said that they would recommend CAB-LA to their male sexual partners. We conclude that willingness to use CAB-LA was high among MSM in Guangxi. However, implementation of CAB-LA faces tough challenges due to its high cost and the low use of PrEP. Peer education may play a large role in the implementation of CAB-LA in China.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10508-024-02886-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Brief Communication: Factors associated with willingness to use long-acting injectable Cabotegravir for HIV pre-exposure prophylaxis (PrEP) among female undergraduate students at a Ugandan university.
AIDS Res Ther
December 2024
Department of Nursing, School of Health Sciences, College of Health Sciences, Makerere University, P. O. Box 7072, Kampala, Uganda.
Background: We assessed the willingness of female students at a Ugandan public university to use long-acting Cabotegravir (CAB-LA) for HIV prevention, given their high prevalence of HIV risk behaviours.
Methods: Using an online questionnaire, this cross-sectional study surveyed 346 female undergraduate students aged 18-25. Factors influencing their willingness were analysed with modified Poisson regression and robust standard errors.
Willingness to pay and price elasticity of demand for long-acting injectable cabotegravir among men who have sex with men in Guangxi, China.
Front Pharmacol
October 2024
Department of Epidemiology and Biostatistics, School of Public Health, Guangxi Medical University, Nanning, China.
Article Synopsis
- A study in Guangxi, China, examined the willingness to pay for long-acting injectable cabotegravir (CAB-LA) among men who have sex with men (MSM) after its 2021 U.S. market release.
- A total of 1,006 participants were surveyed, revealing that the median amount they were willing to pay was 200 CNY per month, with most willing to pay less than 600 CNY.
- Factors influencing willingness to pay included younger age, higher education, higher income, bisexual/unsure orientation, and prior knowledge or use of PrEP, highlighting a significant price elasticity of demand for CAB-LA.
Provider Factors Likely to Impact Access and Uptake of Long-Acting Injectable Cabotegravir for Transgender Women in the United States: Results of a Qualitative Study.
J Assoc Nurses AIDS Care
August 2024
Christine Tagliaferri Rael, PhD, is an Assistant Professor in the University of Colorado College of Nursing, Aurora, Colorado, USA. Doyel Das, BS, is an MPH Student in the Columbia University Mailman School of Public Health, New York, New York, USA. Jonathan Porter, MPH, was an MPH Student in the Columbia University Mailman School of Public Health, New York, New York, USA, and a Professional Research Assistant in the University of Colorado College of Nursing, Aurora, Colorado, USA. He is currently a Research Consultant, Optem Serve Consulting/The Lewin Group, New York, New York, USA. Javier Lopez-Ríos, PhD, MPH is an Assistant Professor in the Dornsife School of Public Health at Drexel University, Philadelphia, Philadelphia, USA. Elena Abascal, DNP, NP, was a DNP student at the Columbia University School of Nursing, New York, New York, USA, and a Clinical Research Nurse at the New York State Psychiatric Institute (NYSPI), New York, New York, USA. She is currently a Nurse Practitioner, Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital, New York, New York, USA. Curtis Dolezal, PhD is an Assistant Clinical Professor in the HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute/Columbia University Psychiatry, New York, New York, USA. Michael P. Vaughn, PhD, MPH was a Postdoctoral Research Fellow in the HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute/Columbia University Psychiatry, New York, New York, USA. He is currently the Research Operations Lead (Experience Design), Capital One Bank, New York, New York, USA. Pilar Giffenig, DNP, MSN, APRN, FNP-C, was a DNP student at the Columbia University School of Nursing, New York, New York, USA, and a Clinical Research Nurse at the New York State Psychiatric Institute, New York, New York, USA. She is currently a Nurse Practitioner, RemoteFocus, New York, New York, USA. Jasmine M. Lopez, BS, is a Research Assistant in the HIV Center for Clinical and Behavioral Studies at NYSPI/Columbia University Psychiatry, New York, New York, USA. Samantha Stonbraker, PhD, MPH, RN, is an Assistant Professor in the University of Colorado College of Nursing, Aurora, Colorado, USA. Christina Sun, PhD, is an Associate Professor in the University of Colorado Collee of Nursing, Aurora, Colorado, USA. Roque Anthony Velasco, MS, NP, is a PhD Student in the University of Colorado College of Nursing, Aurora, Colorado, USA. Leandra Bitterfeld, RN, is a PhD Student in the University of Colorado College of Nursing, Aurora, CO, USA. Walter O. Bockting, PhD, is a Professor and Co-Chief of the Gender Health and Sexuality Area at New York State Psychiatric Institute/Columbia University, New York, New York, USA, and a Professor in the Columbia University School of Nursing, New York, New York, USA. Jose Bauermeister, PhD, MPH, FSBM, is a Professor in the School of Nursing and School of Medicine and the Albert M Greenfield University Professor of Human Relations at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Long-acting injectable cabotegravir (CAB-LA) was US Food and Drug Administration-approved in 2021. However, little is known about providers' CAB-LA knowledge, attitudes, challenges, and prescribing preferences for transgender women patients. Understanding this is critical to developing new pre-exposure prophylaxis (PrEP) interventions tailored to transgender women.
View Article and Find Full Text PDFWillingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Men Who Have Sex with Men in Guangxi, China.
Arch Sex Behav
July 2024
Department of Epidemiology and Biostatistics, School of Public Health, Guangxi Medical University, 22, Shuangyong Road, Nanning, 530021, China.
Cabotegravir (CAB-LA), the first long-acting injectable pre-exposure prophylaxis (PrEP), has been approved for use in the USA and is not currently on the market in China. However, willingness to use CAB-LA and associated factors among men who have sex with men (MSM) have not yet been evaluated in China. A cross-sectional study was conducted in Guangxi, China, in 2022 recruiting 1,006 MSM.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!